Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1902

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more

Conditions: Metastatic Prostate Cancer
Interventions: AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Encino, California • South Pasadena, California + 9 more

Conditions: B-cell Non-Hodgkin Lymphoma
Interventions: AZD4512; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation; Drug · Radiation
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Loma Linda, California • Jacksonville, Florida + 5 more

Conditions: Asthma
Interventions: BDA MDI, AS MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 117
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 93 more

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Interventions: AZD3470, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Healthy Participants
Interventions: AZD3974, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: APOL1-Mediated Kidney Disease
Interventions: AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay; Combination Product · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 86
States / cities: Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more

Conditions: Asthma
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 30
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Datopotamab deruxtecan (Dato-DXd), Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 51
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 47 more

Conditions: Erosive Esophagitis
Interventions: Nexium 20mg, Nexium 10mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

About this AstraZeneca sponsor directory page